<DOC>
	<DOC>NCT02915159</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of abatacept compared to placebo in patients with Sjögren's Syndrome.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com ESSDAI score of at least 5 Positive antiSSA/Ro antibody at screening meet the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism Classification Criteria for Sjögren's Syndrome (EULAR SS) Secondary Sjögrens syndrome Active lifethreatening or organthreatening complications of Sjögren'ssyndrome Other medical condition associated with sicca syndrome Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>